CHANGES IN AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR AND PIGMENT EPITHELIAL-DERIVED FACTOR LEVELS FOLLOWING INTRAVITREAL BEVACIZUMAB INJECTIONS FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION OR PATHOLOGIC MYOPIA

Retina ◽  
2008 ◽  
Vol 28 (9) ◽  
pp. 1308-1313 ◽  
Author(s):  
WAI-MAN CHAN ◽  
TIMOTHY Y.Y. LAI ◽  
KWOK-PING CHAN ◽  
HAITAO LI ◽  
DAVID T.L. LIU ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Macular Degeneration ◽  
Intravitreal Bevacizumab ◽  
Age Related Macular Degeneration ◽  
Pathologic Myopia ◽  
Vascular Endothelial ◽  
Pigment Epithelial ◽  
Age Related ◽  
Endothelial Growth Factor

scholarly journals Aqueous Interleukin-6 Levels Are Superior to Vascular Endothelial Growth Factor in Predicting Therapeutic Response to Bevacizumab in Age-Related Macular Degeneration

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Kakarla V. Chalam ◽  
Sandeep Grover ◽  
Kumar Sambhav ◽  
Sankarathi Balaiya ◽  
Ravi K. Murthy
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Macular Degeneration ◽  
Interleukin 6 ◽  
Intravitreal Bevacizumab ◽  
Age Related Macular Degeneration ◽  
Vascular Endothelial ◽  
Age Related ◽  
Endothelial Growth Factor ◽  
Sd Oct

Objective. To prospectively evaluate the effect of intravitreal bevacizumab on aqueous levels of interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) in patients with exudative age-related macular degeneration (AMD) and correlate clinical outcomes with cytokine levels.Methods. 30 eyes of 30 patients with exudative AMD underwent intravitreal injection of bevacizumab three times at monthly intervals. The aqueous samples prior to the 1st injection (baseline) and 3rd injection were analyzed for VEGF and IL-6 levels. Subjects were subgrouped based upon change in the central subfield (CSF) macular thickness on SD-OCT at 8 weeks. Group 1 included patients (n=14) with a decrease in CSF thickness greater than 10% from the baseline (improved group). Group 2 included patients (n=16) who had a decrease in CSF thickness 10% or less (treatment-resistant).Results. In subgroup analysis, in both groups 1 and 2 patients, compared to aqueous VEGF, aqueous IL-6 levels showed a better correlation with CSF thickness on SD-OCT (r=0.72and 0.71, resp.).Conclusions. Aqueous IL-6 may be an important marker of treatment response or resistance in wet macular degeneration. Future therapeutic strategies may include targeted treatment against both VEGF and IL-6, in patients who do not respond to anti-VEGF treatment alone.

Four‐week outcomes of vascular endothelial growth factor inhibitors for neovascular age‐related macular degeneration

2020 ◽  
Vol 48 (7) ◽  
pp. 946-955
Author(s):  
Shaan Wiryasaputra ◽  
Vuong Nguyen ◽  
Jennifer J. Arnold ◽  
Ross Ferrier ◽  
Peter Hinchcliffe ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Vascular Endothelial ◽  
Age Related ◽  
Endothelial Growth Factor
Sign in / Sign up

Export Citation Format

Share Document